Neurotech Seeks FDA Orphan Drug Status for Rett Syndrome

Neurotech International Ltd. (AU:NTI) has released an update.

Neurotech International Ltd, a biopharmaceutical company specializing in pediatric neurological disorders, has applied for orphan drug designation from the FDA for NTI164 as a potential treatment for Rett Syndrome, a rare genetic condition. The designation could provide incentives such as tax credits, fee waivers, and exclusive marketing rights for seven years post-approval. NTI164, derived from a unique cannabis strain, has shown promise in pre-clinical studies for its neuroprotective properties.

For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.